IMR Press / EJGO / Volume 39 / Issue 1 / DOI: 10.12892/ejgo3798.2018

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Human papillomavirus DNA testing as a screen for cervical cancer: a meta-analysis of randomized controlled trials
Show Less
1 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
2 Department of neurosurgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Eur. J. Gynaecol. Oncol. 2018, 39(1), 10–13; https://doi.org/10.12892/ejgo3798.2018
Published: 10 February 2018
Abstract

Purpose: The aim was to evaluate the effectiveness of cervical screening when HPV DNA testing is implemented. Materials and Methods: Medline (PubMed) was searched and experts were contacted for references. Odds ratio (OR) and 95% confidence intervals (CI) were used as measures of effect sizes. Results: The rate of CIN3 and worse decreased about twofold, from 1.19% in round 1 to 0.67% in round 2, and CIN2 decreased from 1.70% in round 1 to 0.80% in round 2. When primary cervical screening with LBC was combined with HPV testing, there was a statistically significant reduction in the detection of CIN2 and CIN3+ at the next screening round compared with liquid-based cytology (LBC) alone. Conclusions: HPV DNA-based screening is more effective than cytology in CIN3 and invasive cervical cancers, by detecting persistent high-grade lesions earlier, and providing a longer low-risk period. However, in younger women, HPV screening leads to over-diagnosis of regressive CIN2.
Keywords
Human papillomavirus
Cervical cancer
Screening
Share
Back to top